CBDY

Target Group Inc.
3 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 60% | 3/31/2026 | margin expansionBEARISH | 90% | 3/31/2026 | debt restructureBEARISH | 80% | 3/31/2026 | earnings missNEUTRAL | 50% | 3/31/2026 | capital raiseBEARISH | 90% | 5/15/2026 | margin compressionNEUTRAL | 60% | 5/15/2026 | capital raiseBEARISH | 80% | 5/15/2026 | earnings missNEUTRAL | 40% | 5/15/2026 | regulatory actionBEARISH | 90% | 5/15/2026 | margin compressionNEUTRAL | 60% | 5/15/2026 | capital raiseBEARISH | 80% | 5/15/2026 | earnings missNEUTRAL | 40% | 5/15/2026 | regulatory actionMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 15

Gross profit fell 75% YoY as COGS now consumes 78% of revenue.

margin compression
90%
neutralMay 15

Continued reliance on high-interest related-party loans to fund operations.

capital raise
60%
bearishMay 15

Net loss increased from $108k to $550k year-over-year.

earnings miss
80%
neutralMay 15

Disclosure controls and procedures were deemed ineffective as of March 31, 2026.

regulatory action
40%
bearishMay 15

Gross profit fell 75% YoY as COGS now consumes 78% of revenue.

margin compression
90%
neutralMay 15

Continued reliance on high-interest related-party loans to fund operations.

capital raise
60%
bearishMay 15

Net loss increased from $108k to $550k year-over-year.

earnings miss
80%
neutralMay 15

Disclosure controls and procedures were deemed ineffective as of March 31, 2026.

regulatory action
40%
bullishMar 31

Maintained gross margins near 53% despite domestic price compression.

margin expansion
60%
bearishMar 31

Breached related-party loan agreements, forcing reclassification of debt to current.

debt restructure
90%
bearishMar 31

Net loss of $1.36M and revenue decline of 41% year-over-year.

earnings miss
80%
neutralMar 31

Active search for equity financing to cover $11M working capital deficit.

capital raise
50%

Filing History

10-QMay 15, 2026

The 10-Q filing reveals a company at a crossroads, where the potential of a global CPG pivot is clashing with a severe liquidity crisis. While the shift toward international wholesale markets is a logical strategic move to escape the Canadian price war, the execution is being hampered by an unsustainable capital structure. The company is effectively borrowing from related parties at predatory rates to fund basic operations, creating a race against time to achieve profitability before the debt becomes unmanageable. Investors are left weighing the ability of management to monetize its intellectual property and international footholds against the reality of a negative equity position and ineffective internal controls. The critical path forward depends on whether the company can convert its current international sales into a sustainable cash flow that can service its debt and fund the production of its promised CPG lines without further diluting shareholders or increasing its leverage.

10-KMar 31, 2026

The 10-K filing for Target Group Inc. reveals a company at a critical crossroads, where a promising strategic pivot toward international exports is being throttled by a catastrophic balance sheet. While the company has successfully maintained gross margins and reduced overhead, these operational wins are overshadowed by a massive working capital shortfall and a looming debt crisis. The tension between the company's high-quality genetic assets and its near-zero liquidity creates a high-risk, high-reward scenario. Ultimately, the filing highlights a fundamental disconnect between the company's long-term vision and its immediate survival needs. The ability to transition into a lean, export-driven platform depends entirely on the company's capacity to secure additional financing or restructure its related-party debt without further crippling existing shareholders. Until a concrete capital infusion or a major international contract is realized, the company remains a speculative venture fighting against a ticking clock of insolvency.